Physician profile
Frank E Molls
NPI 1639147382
$6,321.35
in general payments reported to CMS, 2019-2025
30 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,270 · 2020: $603 · 2021: $542 · 2022: $717 · 2023: $1,026 · 2024: $1,081 · 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,188.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,653.62 | 2019-2025 | |
| Abbott Laboratories | $1,294.45 | 2019-2024 | Gallant, Assurity, Fortify Assura |
| Amgen INC. | $452.49 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $420.13 | 2021-2025 | Verquvo |
| Pfizer INC. | $418.05 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $284.43 | 2019-2023 | Xarelto |
| Cvrx, INC. | $267.39 | 2024-2025 | Barostim Neo System |
| Astellas Pharma US INC | $251.08 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $204.67 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $139.18 | 2019-2020 | |
| Amarin Pharma, INC. | $93.45 | 2019-2021 | |
| Edwards Lifesciences Corporation | $92.61 | 2023-2025 | Pascal, Sapien 3 Ultra Resilia |
| Actelion Pharmaceuticals US, INC. | $87.51 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.19 | 2019-2024 | Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $75.82 | 2021-2023 | Arcalyst |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $71.30 | 2024 | Arcalyst |
| Philips North America LLC | $63.21 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $54.19 | 2023-2024 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $51.05 | 2022-2025 | Eliquis |
| Kestra Medical Technology Services, INC. | $39.33 | 2022-2023 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $36.58 | 2019-2023 | |
| Alnylam Pharmaceuticals INC. | $35.54 | 2023-2025 | Amvuttra |
| Medtronic Vascular, INC. | $25.28 | 2020 | |
| Bardy Diagnostics, INC. | $25.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.44 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.39 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $17.18 | 2020 | |
| Chiesi USA, INC. | $15.98 | 2021 | |
| Gilead Sciences, INC. | $13.35 | 2019 | |
| Esperion Therapeutics, INC. | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Molls listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.